Financing ·
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on September 8, 2026, to furnish an updated investor presentation…
SXTP60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on September 8, 2026, to furnish an updated investor presentation dated for the same day under Item 7.01 of Regulation FD. The presentation outlines the company's strategy to expand its marketed antimalarial product ARAKODA (tafenoquine) into treatments for tick-borne diseases, specifically babesiosis. It details a commercial base generating $208k in Q2 2026 net product revenue and highlights a July 31, 2026 private placement that raised approximately $1.0M at $1.74 per share. The company reports pro forma cash and equivalents of roughly $1.0M as of late July, providing an operating runway into early October 2026. The filing also notes a Series A non-voting convertible preferred stock balance with a 6% cumulative dividend following a Knight conversion. This biopharmaceutical company focuses on targeted therapies for vector-borne diseases.